2.3%

Junshi Biosciences Announces FDAs Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC PatientsJunshi Biosciences Announces FDAs Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients

Junshi Biosciences Announces FDAs Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients

SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading…

4 weeks ago
RESTEM to Present Phase 2/3 IIMPACT Trial Design in Idiopathic Inflammatory Myopathy at EULAR 2025 CongressRESTEM to Present Phase 2/3 IIMPACT Trial Design in Idiopathic Inflammatory Myopathy at EULAR 2025 Congress

RESTEM to Present Phase 2/3 IIMPACT Trial Design in Idiopathic Inflammatory Myopathy at EULAR 2025 Congress

June 06, 2025 16:07 ET  | Source: Restem MIAMI, June 06, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology…

5 months ago